ATP-P2X7 Receptor Modulates Axon Initial Segment Composition and Function in Physiological Conditions and Brain Injury

Ana del Puerto1,2, Laura Fronzaroli-Molinieres5,6, María José Perez-Alvarez3, Pierre Giraud5,6, Edmond Carlier5,6, Francisco Wandoosell2,4, Dominique Debanne5,6 and Juan José Garrido1,2

1Instituto Cajal, CSIC, Department of Cellular, Molecular and Developmental Neurobiology, Madrid 28002, Spain, 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain, 3Departamento de Biología (Unidad Docente Fisiología Animal), Universidad Autónoma de Madrid, Madrid 28049, Spain, 4Centro de Biología Molecular, CSIC-UAM, Madrid 28049 Spain, 5Institut National de la Santé et de la Recherche Médicale, U1072, Marseille F-13344 France and 6Aix-Marseille Université, Faculté de Médecine Secteur Nord, Marseille F-13344 France

Address correspondence to Juan José Garrido, PhD, Instituto Cajal, CSIC, Avenida Doctor Arce, 37, Madrid 28020, Spain.
Email: jjgarrido@cajal.csic.es

Axon properties, including action potential initiation and modulation, depend on both AIS integrity and the regulation of ion channel expression in the AIS. Alteration of the axon initial segment (AIS) has been implicated in neurodegenerative, psychiatric, and brain trauma diseases, thus identification of the physiological mechanisms that regulate the AIS is required to understand and circumvent AIS alterations in pathological conditions. Here, we show that the purinergic P2X7 receptor and its agonist, adenosine triphosphate (ATP), modulate both structural proteins and ion channel density at the AIS in cultured neurons and brain slices. In cultured hippocampal neurons, an increment of extracellular ATP concentration or P2X7-green fluorescent protein (GFP) expression reduced the density of ankyrin G and voltage-gated sodium channels at the AIS. This effect is mediated by P2X7-regulated calcium influx and calpain activation, and impaired by P2X7 inhibition with Brilliant Blue G (BBG), or P2X7 suppression. Electrophysiological studies in brain slices showed that P2X7-GFP transfection decreased both sodium current amplitude and intrinsic neuronal excitability, while P2X7 inhibition had the opposite effect. Finally, inhibition of P2X7 with BBG prevented AIS disruption after ischemia/reperfusion in rats. In conclusion, our study demonstrates an involvement of P2X7 receptors in the regulation of AIS mediated neuronal excitability in physiological and pathological conditions.

Keywords: ankyrin G, axon initial segment, BBG, brain ischemia, P2X7 receptor, sodium channels

Introduction

The axon initial segment (AIS) is not only the locus of action potential initiation (Kole et al. 2008) but it also plays an essential role in maintaining axon integrity and identity (Hedstrom et al. 2008). The property of spike initiation is conferred by the high concentration of voltage-gated ion channels in the AIS (Bender and Trussell 2012) maintained by cytoskeletal proteins, such as ankyrin G or PSD-93 (Garrido et al. 2003; Pan et al. 2006; Ogawa et al. 2008). The cellular and molecular machinery that finely modulates functional expression of ion channels at the AIS remains mostly unknown. Recent studies have shown that kinases in the AIS (i.e., Casein kinase 2, GSK-3, and cdk5) can modulate the density of AIS proteins (Brechet et al. 2008; Sanchez-Ponce et al. 2011; Vacher et al. 2011; Tapia et al. 2013). Moreover, neuronal excitability is also controlled in certain neuronal types through modifications of the position and length of the AIS (Grubb and Burrone 2010; Kuba et al. 2010). This AIS plasticity is controlled at least by the influx of calcium through T- and/or L-type voltage-gated calcium channels or metabotropic glutamate receptors and higher physiological [Ca2+]i, that modulate calcineurin activity (Evans et al. 2013). Besides physiological regulation of the AIS, AIS alterations have been reported in neurological disorders and nervous system injury (Buffington and Ransbard 2011). In this context, some neurological disorders, such as Angelman syndrome or schizophrenia; or brain trauma are related to structural alterations of the AIS or changes in the expression of structural proteins and ion channels in the AIS (Cruz et al. 2009; Kaphzan et al. 2011; Baalman et al. 2013; Hinman et al. 2013). Moreover, AIS is disrupted after brain ischemia by a calcium/calpain-dependent mechanism, independent of N-methyl-D-aspartate (NMDA) receptor activation (Schafer et al. 2009). In this sense, P2X purinergic receptors are good candidates to control calcium influx in physiological and pathological conditions.

Seven P2X receptors have been cloned (P2X1-7). They are all expressed in neurons and glial cells during brain development and in adult brain. These receptors are activated by extracellular adenosine 5’-triphosphate (ATP) and allow calcium influx to the same extent as NMDA receptors (Abbracchio et al. 2009). Among the 7 P2X purinergic receptors, P2X7 is the one that needs higher ATP concentrations (>100 μM) for its activation (North and Surprenant 2000). In addition, it has been proposed that P2X7 receptor triggers quantal release of ATP (Gutierrez-Martin et al. 2011). P2X7 receptor stimulation has been implicated in several nervous system diseases, such as brain ischemia, epileptic seizures, multiple sclerosis, spinal cord injury, Alzheimer’s disease, or Huntington’s disease (Vianna et al. 2002; Parvathenani et al. 2003; Wang et al. 2004; Matute et al. 2007; Diaz-Hernandez et al. 2009; Kim et al. 2009; Arbeloa et al. 2012). Furthermore, recent studies have shown that suppression or inhibition of P2X7 receptor promotes axonal growth, suggesting a role of their antagonists in axonal regeneration and axonal physiology (Diaz-Hernandez et al. 2008; del Puerto et al. 2012).

Our study demonstrates that an increase in the extracellular ATP concentration reduces the density of βIV-spectrin, ankyrin G, and voltage-gated sodium channels at the AIS, via a process that depends on P2X7 activity, calcium, and calpain. In this sense, we show that AIS disruption observed after brain ischemia is prevented by a P2X7 receptor antagonist. Finally,
electrophysiological studies in brain slices show P2X7 involvement in the modulation of sodium currents, action potential generation and neuronal excitability. Thus, our study suggests a new role for purines and ATP-gated P2X7 purinergic receptors in the regulation of the AIS.

Materials and Methods

**Reagents and Plasmid**

ATP (A5394), Brilliant Blue G (BBG, B0770) and ethyleneglycol-bis (2-aminoethyl ether)-N,N′,N′,N′-tetra acetic acid (EGTA) (E3889) were obtained from Sigma-Aldrich, Calpeptin was from Calbiochem (03340051) and MDL-28170 from Tocris (1146). GFP plasmid was obtained from Clontech, P2X7-GFP, P2X7 interference RNA and scrambled RNA plasmids used in this study have been used and described in previous publications (Diaz-Hernandez et al. 2008; del Puerto et al. 2012).

**Animals**

Animals were housed in a room at controlled temperature and relative humidity with alternating 12 h light and dark cycles and free access to food and water “ad libitum”. Animal care protocols used in our laboratory are in conformity with the appropriate national legislation (53/2013, BOE no. 1337), and guidelines of the Council of the European Communities (2010/63/UE). All protocols were previously approved by CSIC bioethics committee.

**Induction of Transient Focal Cerebral Ischemia (tMCAO)**

Fifteen adult male Wistar rats ~8 weeks old (250–310 g) obtained from CMB animal facilities were used for the study. Transient focal cerebral ischemia was induced using the intraluminal suture method by the middle cerebral artery occlusion (MCAO) procedure as described previously (Longa et al. 1989). Rats were anesthetized under isoflurane (3% for induction and 1–1.5% for maintenance) delivered via a face mask in oxygen-enriched air. The right common carotid artery (CCA) was exposed and dissected; the right external carotid artery (ECA) and the right middle cerebral artery (MCA). The suture was secured in place with a ligature and was main-
tained for 90 min. After this time the suture was removed thus allowing reperfusion. The sham operated rats received all surgical procedures but without the suture insertion. All animals received ibuprofen (Dalsy, Abbot) at an analgesic, diluted at 200 mg/L in the drinking water for 48 h after surgery. Some rats (sham and tMCAO) were treated with 5 doses of BBG (50 mg/kg), by intraperitoneal injection at 3 and 6 h after reperfusion and then twice a day. All the animals were sacri-
ificed after 72 h of the onset of ischemia.

**Neurologic Deficit Score**

The neurological deficit score of each rat was measured before surgery, during the first 6 h after tMCAO induction and just before administration of BBG, using a slightly modified version of the method described by Yrjanheikki et al. (2005). The neurological deficit score of each rat was performed to check whether ischemia was correctly induced and before each injection. A 6-point neuroscore test of the motor status was recorded. Rats were scored 5 when both forelimbs showed a normal extension towards the floor when lifted; 4 in the case of dysfunctional rats with consistently reduced resistance to lateral push towards the paretic side; 3 when rats did circle towards the paretic side if pulled and lifted by the tail; 2 if circling towards the paretic side when pulled by the tail; 1 when circling towards the paretic side spontaneously and 0 if no spontaneous motion. Additionally the animals were evaluated for any other neurological abnormalities that had not been included in the previous grade scale, such as keeping their balance, sensorial perception (acoustic, visual localization), and reflexes (corneal, palpebral, postural correction). Only ischemic animals that showed a neurological score of 3 or lower during the first 6 h after ischemia induction were included in the study.

**Tissue Collection**

After 72 h of the onset of ischemia, the rats were sacrificed by deep anes-
esthesia by intraperitoneal injection of a mixture of medetomidine (375 μg/kg) and ketamine (112.5 mg/kg). Deeply anesthetized animals were transcardially perfused with ice-cold phosphate-buffered saline (PBS) and then with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Brains were removed and postfixed 1 h at 4°C. Subsequently, the brains were washed 3 times in PBS (15 min each), and cryoprotected in 30% sucrose in PBS at 4°C for 48–72 h. Finally, the brains were embedded in Tissue-Tek medium (Sakura, Zoeterwoude, NL) and stored at −20°C until used. Coronal cryostat sections (30-μm thick) were obtained from each brain and sections located from +2 to −2 relative to the bregma were selected for immunohistochemistry experiments.

**Neuronal Culture**

Mouse hippocampal neurons were prepared as previously described (Kaech and Banker 2000). Neurons were obtained from E17 mouse hippocampi, which were incubated in a 0.25% trypsin solution in Ca2+/Mg2+ free Hank’s buffered salt solution (HBBS) and dissociated using fire polished Pasteur pipettes. The cells were plated on polylysine-coated coverslips (1 mg/mL) at a density of 5000 cells/cm² for 2 h in plating medium (minimum essential medium [MEM], 10% horse serum, 0.6% glucose, Glutamax-I and antibiotics). Then, coverslips were inverted and transferred to culture dishes containing astrocytes. Astrocytes medium was replaced by neuronal culture medium 24 h before (Neurobasal medium, B27 supplement, Glutamax-I). To avoid contact between neurons and astrocytes paraffin beads were placed on coverslips before neuronal plating. 5 μM 1-β-D-arabinofuranosylcytosine (AraC) was added after 2 days in culture to avoid glial proliferation. Primary hippocampal neurons were nucleo-
fected using the Amaxa nucleofector kit for primary mammalian neural cells (Amaxa Bioscience) according to the manufacturer’s instructions. Nucleofection was performed using 3 μg total DNA and 3 × 105 cells for each nucleofection. Nucleofection efficiency was ~15% of neurons, based on the number of GFP positive neurons.

**Immunofluorescence**

Coverslips were treated for 10 min with 50 mM NH4Cl and incubated in blocking buffer (0.22% gelatin, 0.1% Triton X-100 in PBS) for 30 min, before incubation with primary antibodies for 1 h at room temperature in blocking buffer. Brain sections were incubated in blocking buffer (10% goat serum, Triton X-100 0.5% in PBS) for 1 h before overnight incubation with primary antibodies in the same buffer. The primary antibodies used were: chicken anti-MAP2 (1:10 000, Abcam), mouse anti-PanNaCh (1:75, Sigma), mouse antiankyrin G (1:100) from Neuro-
Mab; Rabbit anti βV-spectrin (1:500), kindly provided by Dr Matthew Rasband (Baylor College, Houston). The secondary antibodies used were a donkey antimouse, antirabbit, or antichicken Alexa-Fluor-488, 594, or 647 (1:500). Nuclei were stained using 4',6-diamidino-2-phenylindole, and coverslips were mounted in Fluromount G. Images were acquired on a vertical Axioskop-2plus microscope (Zeiss) or a confocal microscope (LSM510, Zeiss) under the same conditions to compare intensities. Figures were prepared for presentation using the Adobe CS3 software. Quantification of fluorescence intensity at the AIS was performed in 150 neurons per experimental condition in 3 inde-
pendent experiments. Measurements of AIS proteins location and in-
tensity in immunocytochemistry experiments were performed with confocal images using Matlab script according to Grubb and Burrone (2010). Briefly, image stacks were converted into single maximum intensity z-axis projections, exported as raw 16-bit TIFF files, and imported into Matlab (Mathworks) for analysis using Matlab script.
We drew a line profile starting at the soma that extended through the axon, past the AIS. At each pixel along this profile, fluorescence intensity values were averaged over a 3 × 3 pixel square centered on the pixel of interest. Averaged profiles were then smoothed and normalized to between 1 (maximum smoothed fluorescence, location of the AIS max position) and 0 (minimum smoothed fluorescence) and finally were normalized to the mean control value in each experiment. AIS start and end positions were obtained at the proximal and distal axonal positions, respectively, where the normalized profile declined to 0.33.

**Hippocampal Slices Cultures and Biologic Transfection**

Slice cultures containing the hippocampus and entorhinal cortex were obtained from postnatal day 7 mice as previously reported (Debanne et al. 2008). Slices (350–450 µm) were cut in sucrose-based slicing solution (280 mM sucrose, 26 mM NaHCO3, 1.3 mM KCl, 1 mM CaCl2, 10 mM MgCl2, 11 mM Na-glucose, 50 mM phenol red, and 2 mM kynurenic acid) and were maintained for 1 h at room temperature in oxygenated (95% O2/5% CO2) standard artificial cerebrospinal fluid (125 mM NaCl, 2.5 mM KCl, 0.8 mM NaH2PO4, 26 mM NaHCO3, 3 mM CaCl2, 2 mM MgCl2, and 11 mM Na-glucose). Each slice was placed on 20-mm latex membranes (Millipore) inserted into 35-mm Petri dishes containing 1 mL of culture medium (25 mL MEM, 12.5 mL HBSS, 12.5 mL horse serum, 0.5 mL penicillin/streptomycin, 0.8 mL glucose solution (1M), 0.1 mL ascorbic acid solution (1 mg/mL), 0.4 mL 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (1M), 0.5 mL B27, and 8.95 mL water) and kept at 34°C, 95% O2/5% CO2. To arrest glial proliferation, 5 µM Ara-C was added to the culture medium. BBG treatment carried out at a concentration of 200 nM the next day and kept for 2 days before electrophysiological experiments. For transfection experiments, GFP or P2X7-GFP plasmids were delivered at a pressure of 100 dpi into brain slices using the Helyos gene-gun system (Bio-Rad) according to the manufacturer’s instructions. Briefly, gold particles covered with each plasmid were delivered at a pressure of 100 dpi into brain slices cultured for 2 days, and then brain slices were kept for a further 48 h before electrophysiological recording or fixation for immunohistochemistry. Slices were fixed for immunohistochemistry using 4% PFA for 1 h and washed in PBS. Slices were incubated overnight with primary antibody: rabbit anti-IV-spectrin; in PBS containing 20% goat serum and 0.5% Triton X-100. Secondary antibody was incubated for 4 h before mounting brain slices in Fluoromount-G. Confocal images were acquired on a Leica TCS SP2 laser scanning microscope (Leica Microsystems).

**Electrophysiological Studies**

Whole-cell patch clamp recordings were obtained from CA3 or L5 pyramidal neurons. The external solution contained (mM): 125 NaCl, 26 NaHCO3, 3 CaCl2, 2.5 KCl, 2 MgCl2, 0.8 NaH2PO4, and 10 n-glucose, and was equilibrated with 95% O2–CO2. Patch pipettes (5–10 MΩ) were filled with a solution containing (mM): 120 potassium gluconate, 20 KCl, 0.5 EGTA, 10 HEPES, 2 NaATP, 0.3 NaGTP and 2 MgCl2, pH 7.4. Recordings were made at 29°C. The voltage and current signals were low-pass filtered (3 kHz) and acquisition of sequences (500–1500 ms) was performed at a frequency of 0.1 Hz with P-clamp 8 or 10 (Axon Instruments). Sodium currents were evoked by a voltage step (50 ms) from −70 to 0 mV. The capacitive and leak components of the evoked current were subtracted with a conventional P/4 protocol. Intrinsically excitable cells were monitored with depolarizing current pulses (1 s) of increasing amplitude (from +10/+500 pA).

**Statistical Analysis**

Statistical analysis was carried out in Sigmastat v11 (Systat Software Inc.). Data for each independent sample were obtained from at least 3 independent experiments. Data from each experiment were collected from at least 50 cells (between 50 and 80 cells) in each experimental sample. We compared the data from each 2 experimental samples using a t-test. Before carrying out the test, Sigmastat software did check for normal distribution of data. Some data sets failed the normality test (Shapiro–Wilks test). For that reason, we used a nonparametric Mann–Whitney U-test for all 2 independent sample comparisons (data in Figs 1–5). All tests were 2-tailed. Differences were considered significant when P < 0.05. Electrophysiological data were compared using a t-test.

**Results**

**P2X7 Activity Modulates AIS Structure and Protein Composition**

Calcium is an important regulator of AIS function and is also involved in AIS disruption in brain ischemia. However, AIS disruption is not rescued after ischemia by an NMDA antagonist (Schafer et al. 2009). As mentioned above, P2X7 receptor allows calcium influx to the same extent as NMDA receptors. In order to analyze whether P2X7 receptors are involved in the regulation of the AIS, we treated 20 DIV hippocampal neurons with ATP, the P2X7 receptor agonist, increasing the concentration of ATP in the extracellular medium (+1 mM) for 24 h. ATP treatment significantly reduced the concentration of ankyrin G at the AIS (Fig. 1A,C), sparing only 62.3 ± 2.7% of the fluorescence observed in control neurons (100%). This reduction was observed all along the AIS (Fig. 1D), without any change in AIS length or position (Supplementary Fig. 1). Similar results were obtained for voltage-gated sodium channels (PanNaC), 70.6 ± 4.7% compared with control neurons (Fig. 1B,E). Interestingly, cotreatment with ATP (+1 mM) and BBG (100 nM) for 24 h not only prevented this reduction but significantly increased ankyrin G (111.4 ± 3.9%, Fig. 1A,C) and PanNaCh (118.1 ± 7.1%) (Fig. 1B,E). BBG treatment alone also increased the density of AIS proteins (Fig. 1A–D). Hence, inhibition of P2X7 receptors prevents the loss of AIS proteins produced by elevated extracellular ATP.

We then asked whether BBG-mediated P2X7 receptor inhibition could rescue the loss of AIS proteins induced by ATP treatment. Thus, neurons previously exposed to ATP (+1 mM) for 21 h were treated with increasing concentrations of BBG (10, 50, and 100 nM) for 3 additional hours maintaining ATP treatment (Fig. 2A). In these experimental conditions, concentrations of 50 nM BBG or higher rescued ankyrin G staining at the AIS from 60.5 ± 2.5% in ATP treated neurons to 78.3 ± 2.9% (Fig. 2A,D). This rescue was not observed in control neurons (Fig. 2A–C). Similar results were obtained for voltage-gated sodium channels (Fig. 2D,E). This result confirms a role of the P2X7 receptor in modulating density of AIS proteins.

In view of these results and to further substantiate the role of P2X7, hippocampal neurons were nucleofected, before plating, with plasmids expressing GFP or P2X7-GFP, and plasmids that coexpress P2X7 interference RNA (sh P2X7) or its corresponding scrambled interference RNA (sc shRNA) and GFP. Neurons were maintained 20 DIV and treated with BBG (100 nM) or ATP (+1 mM) in different experimental conditions. AISs of neurons expressing P2X7-GFP receptor displayed only 60.4 ± 4.1% and 67.3 ± 4.3% of the fluorescence quantified in GFP-nucleofected neurons for ankyrin G or sodium channel, respectively (Fig. 3A,C,D). Ankyrin G and sodium channel fluorescence in GFP-nucleofected neurons was equal to that observed in surrounding nonnucleofected neurons. This reduction of AIS proteins produced by P2X7-GFP expression was prevented, and expression was even increased, by combined treatment with BBG for the last 24 h (116 ± 6.8%, PanNaC and 124.7 ± 9.4%, ankyrin G), as previously shown.
for BBG in experiments where neurons were treated with the P2X7 agonist ATP (Fig. 1A,C,D). Next, we nucleofected neurons with P2X7 interference RNA or scrambled interference RNA to analyze the effect of ATP on AIS proteins in neurons with reduced P2X7 function. The expression of P2X7 interference RNA significantly increased the expression of ankyrin G (135.7 ± 11.5%), indicating a role for P2X7 in the downregulation of AIS protein tethering at the AIS. This fact was confirmed when neurons expressing P2X7 interference RNA were treated with ATP. While neurons that were non-nucleofected or nucleofected with scrambled interference RNA showed a decreased AIS protein staining (75.9% ± 4.7%), those with reduced P2X7 expression were not affected by ATP treatment, and ankyrin G and sodium channels staining at the AIS was similar to control neurons in the absence of ATP treatment, 113.9 ± 10.4% and 116.2 ± 9.8%, respectively. (Fig. 3B,E,F).

These data demonstrate a role for P2X7 and extracellular ATP in the regulation of AIS proteins, which then raises the question as to the molecular mechanisms modulated by P2X7 that regulate the tethering and maintenance of proteins at the AIS?

**P2X7 Modulation of AIS Proteins is Mediated by Calcium and Calpain**

Activation of P2X7 by ATP triggers calcium influx and increased intracellular calcium concentration. Calcium entry is mediated directly by P2X7 purinoreceptor, but also by indirect opening of voltage-dependent calcium channels to further increase [Ca$^{2+}$], Studies in NG108-15 cells demonstrate that at least 31% of ATP-mediated calcium influx is not prevented by a combination of voltage-dependent calcium channels blockers (Brater et al. 1999), which in contrast prevents completely the KCl mediated intracellular calcium increase. Thus, we first checked the effect of increased extracellular calcium concentration on the AIS. The extracellular calcium concentration was
increase the calcium concentration of the medium. The change in calcium concentration was mediated by the P2X7 receptor (Fig. 4A). Then, we analyzed whether decreasing the extracellular calcium concentration with EGTA prevented the ATP-mediated reduction of ankyrin G. In fact, treatment of neurons for 24 h with ATP in the presence of 2 mM EGTA preserved ankyrin G levels (89.8 ± 6.2% vs. 58.2 ± 2.8% in ATP-treated neurons) (Fig. 4B). Similar results were obtained for voltage-gated sodium channels (Fig. 4C,F), for which expression at the AIS was reduced by increased extracellular calcium concentration and ATP, and stabilized by EGTA or BBG. These data were confirmed in neurons expressing P2X7-GFP or P2X7 interference RNA. The addition of 2 mM CaCl2 to the medium failed to decrease ankyrin G levels in neurons when P2X7 receptor expression was reduced by interference RNA (100.1 ± 10.9% vs. 50.1 ± 3.4% in scrambled shRNA nucleofected neurons; Fig. 4D), demonstrating that calcium-mediated reduction of AIS proteins depends on P2X7. In a similar way, sequestering extracellular calcium with 2 mM EGTA blocked the reduction in the concentration of AIS proteins mediated by P2X7-GFP (109.7 ± 6.8% vs. 63.6 ± 3.7% for ankyrin G and 99.4 ± 7.7% vs. 67.8 ± 4.3% for PanNaCh; Fig. 4D,E,G). Once a role for calcium and P2X7 in AIS regulation was confirmed and taking into account that the inhibition of calpain, a calcium-activated protease, prevents AIS injury (Schafer et al. 2009), we analyzed whether calpain inhibitors (calpeptin and MDL) could prevent the decrease in AIS proteins mediated by ATP and P2X7.

**P2X7 Receptors Modulate Voltage-gated Sodium Currents and Neuronal Excitability**

All these data suggest that changes in P2X7 receptor activity are important for the regulation of voltage-gated ion channels at the AIS, implicating this receptor in the modulation of neuronal excitability. To corroborate the data obtained in hippocampal cultured neurons and consolidate this latter hypothesis, hippocampal slice cultures containing the entorhinal cortex were used. Slices were treated with the P2X7 antagonist, BBG and kept in culture for at least 48 h before testing the electrophysiological properties of the neurons (Fig. 6). CA3 pyramidal neurons treated with BBG (200 nM) for 48 h, displayed an enhanced sodium current (148.5 ± 13.8%) compared with control neurons (100 ± 9.9%; Fig. 6A). Then, we analyzed in current clamp whether neuronal excitability and action potential number was altered by the P2X7 antagonist. Consistent with voltage clamp recordings, BBG increased the number of action potentials (Fig. 6B).

To consolidate the role of P2X7 receptors in regulating sodium current and neuronal excitability, we expressed P2X7-GFP receptors in brain slices using the GeneGun.
technique, and due to the low number of hippocampal neurons transfected, we decided to analyze layer 5 pyramidal cortical neurons (Fig. 7). Electrophysiological recordings were made in neurons expressing P2X7-GFP and nearby control neurons to minimize possible variability due to culture conditions or to shot gold particles. Previous studies have shown that GFP expression do not affect neither resting membrane potential, membrane conductance, actions potentials, nor firing accommodation (Ehrengruber et al. 2001). To confirm that P2X7-GFP expression was affecting AIS in brain slices, some slices were fixed and stained with antibodies against ankyrin G or PanNaCh (red). Nucleofected neurons were identified by GFP expression (green). The ×4 magnifications of AISs from nucleofected neurons are shown under each image. Scale bar = 50 μm. (C,E) Quantification of integrated ankyrin G fluorescence intensity at the AIS. (D,F) Quantification of integrated PanNaCh fluorescence intensity. All quantifications were done in at least 50 neurons in each experimental and experiment. Data are represented as the mean ± SEM of at least 3 independent experiments. Individual data were normalized to the control mean. (n.s.: nonsignificant; *P < 0.05; **P < 0.01; ***P < 0.001, Mann–Whitney test).

**Figure 3.** Effects of expression of P2X7 receptor-GFP or P2X7 receptor interference RNA on AIS protein density. Hippocampal neurons were nucleofected with plasmids expressing GFP or P2X7-GFP (A) and scrambled interference RNA or P2X7 interference RNA (B) and maintained in culture for 20 DIV before treatment with BBG or ATP for 24 h. Neurons were fixed and stained with antibodies against ankyrin G or PanNaCh (red). Nucleofected neurons were identified by GFP expression (green). The ×4 magnifications of AISs from nucleofected neurons are shown under each image. Scale bar = 50 μm. (C,D) Quantification of integrated ankyrin G fluorescence intensity at the AIS. (E,F) Quantification of integrated PanNaCh fluorescence intensity. All quantifications were done in at least 50 neurons in each experimental and experiment. Data are represented as the mean ± SEM of at least 3 independent experiments. Individual data were normalized to the control mean. (n.s.: nonsignificant; *P < 0.05; **P < 0.01; ***P < 0.001, Mann–Whitney test).

**P2X7 Antagonism Prevents Injury of the AIS After Brain Ischemia**

Our results demonstrate a role of P2X7 receptor and calcium in AIS modulation. Next, we checked whether the calcium-permeable ATP-gated P2X7 receptor could impair AIS disruption or play a role in AIS modulation in brain ischemia. Transient ischemia was induced by MCAO in 6 rats for 90 min before
allowing reperfusion. In 2 independent set of experiments, rats were separated in 2 groups that were treated intraperitoneally with BBG or vehicle after 3 and 6 h following reperfusion, and then twice a day. A third group was sham-operated without ischemia induction. Motor neuroscore tests gave a score of 5 in sham-operated rats, while rats subjected to ischemia kept the initial score of 3 until 72 h. However, BBG treated rats recovered partially obtaining a score of 4 at 72 h (P < 0.05, t-test).

Our results show a significant reduction in the number of AIS identified by ankyrin G and βIV-spectrin staining in ischemic brain tissue (Fig. 8A,C) compared with contralateral nonischemic cortical region (36.3 ± 7.8%, ipsilateral vs. 100%, contralateral; P < 0.001, n = 5). However, when rats were treated with BBG (50 mg/kg), the number of AIS preserved and identifiable in the ischemia region by ankyrin G and βIV-spectrin staining was significantly increased (88.6 ± 5.9% vs. 36.3.7 ± 7.8% in vehicle treated rats; P < 0.001, n = 5) (Fig. 8B,D). P2X7 staining was not detected at the AIS, suggesting that P2X7 receptors in other neuronal structures regulate AIS structure.

In conclusion, our data demonstrate the involvement of P2X7 receptor activity in the regulation of voltage-gated sodium channels and structural protein density at the AIS, and suggest a major role of the purinergic system in physiological and pathological modulation of neuronal excitability.
Discussion

Ion channel modifications and mutations in the AIS have been related to a variety of brain diseases (for a review see, Buffington and Rasband 2011). Our study demonstrates a new role for P2X7 receptors in the regulation and maintenance of the structural and functional properties of the AIS. P2X7 inhibition not only prevents AIS disruption after MCAO-induced brain ischemia, but also enhances neuronal excitability in cultured brain slices. In fact, ATP-mediated P2X7 activation or its exogenous receptor expression diminishes βIV-spectrin, ankyrin G and voltage-gated sodium channel expression at the AIS in brain slices or cultured hippocampal neurons. This occurs through calcium/calpain-mediated degradation, reducing sodium current amplitude and the number of action potentials. We show that P2X7 receptor is not detectable in the AIS, suggesting that mechanisms outside the AIS may regulate protein expression at the AIS. Furthermore, these results indicate a new major role of the purinergic system in the functional regulation of the AIS in physiological and pathological conditions.

P2X7 Modulation of AIS Function

Brain injury and neurodegenerative disorders are generally due to perturbations in the regulation of glial cells and/or neurons. P2X7 receptors are widely expressed in non-neuronal cells and neurons, and we cannot exclude the participation of non-neuronal P2X7 receptors in more complex models where glial cells are in close contact with neurons. However, our data using a model of pure cultured neurons, where supporting glial cells are not in contact, point to a role of neuronal P2X7 receptor activation by ATP in the loss of AIS proteins. In fact, oxygen/glucose deprivation in cultured cortical or hippocampal neurons, in the absence of glial cells, results in the loss of AIS protein staining (Schafer et al. 2009) and this happens within the first 2 h before cell death. In our study, stimulation of the purinergic system in the functional regulation of the AIS in physiological and pathological conditions.
of P2X7 receptor by ATP diminished the concentration of proteins at the AIS. In contrast, the AIS was still faintly detectable, suggesting that P2X7 receptor exerts a regulatory mechanism that controls the density of AIS proteins without completely disrupting AIS structure. In fact, P2X7 suppression impaired this reduction and even increased sodium channel density, as observed when P2X7 receptor was inhibited by BBG. Moreover, after prolonged ATP treatment, P2X7 inhibition rescued the density of AIS proteins, suggesting that there is a physiological turnover of AIS proteins. Thus, final concentration of some proteins at the AIS may depend on the equilibrium between calpain degradation and membrane insertion at the AIS of proteins from a reserve pool. This hypothesis may explain why P2X7 inhibition with BBG increases AIS proteins density. Further experiments will be necessary to understand how AIS proteins density is regulated and their contribution to neuronal function. Hence, the P2X7 receptor has a physiological role in AIS regulation, besides its pathological role in neurodegenerative diseases, such as Parkinson’s, Alzheimer’s or Huntington’s disease (for a review see, Vosler et al. 2008), and traumatic brain or spinal cord injury (Kampf et al. 1996; Ray et al. 2003). Calcium (and subsequently calpain) disrupts the AIS cytoskeleton. This process is thought to account for the AIS dissipation observed in brain ischemia since it is prevented by the calpain inhibitor MDL-28170 (Schafer et al. 2009). Calpain is activated by increased intracellular calcium concentration. Our data show that the P2X7 receptor mediates the calcium influx at the origin of these alterations in the AIS. We cannot exclude that voltage-gated calcium channels have a minor contribution as they may be opened as a consequence of P2X7 activation. In fact, Brater et al. (1999) described in NG108-15 cells that 28% of ATP-induced calcium influx is blocked by the L-type calcium channels blocker, nifedipine. Recent evidences show that calcium influx through L-type voltage-gated calcium channels is involved in the modulation of another type of AIS plasticity, modulating AIS position or length (Grubb and Burrone 2010; Kuba et al. 2010). However, authors did not report any change in AIS proteins density, and our study shows that P2X7 mediated mechanisms do not change AIS position or length (Supplementary Fig. 1). Thus, our data suggest that ATP-mediated activation of P2X7 receptors control a different type of AIS plasticity in response to different stimulus. Even more, calcium mediated modulation of AIS position do not depend on calpain, but instead needs calcineurin activation (Evans et al. 2013). In fact, we show that calcium-dependent alterations in the AIS were abolished by calpain inhibitors, P2X7 receptor inhibition or P2X7 knockdown. Reciprocally, extracellular calcium depletion impaired the reduction in AIS protein density induced by ATP or P2X7-GFP expression. Moreover, it has been reported that P2X7 activation by ATP induces calpain-dependent protein cleavage in cortical neurons and Par C5 cells (Hwang et al. 2009; Nishida et al. 2012). Furthermore, recent studies have shown that βIV-spectrin, ankyrin G, and voltage-gated sodium channels are substrates for calpain (Schafer et al. 2009; von Reyn et al. 2009). This may account for the reduction of βIV-spectrin, ankyrin G, and sodium channels at the AIS observed in our study, and its recovery by calpain inhibitors, P2X7 antagonist or P2X7 interference RNA.

**P2X7 Involvement in AIS Disruption During Brain Ischemia**

Due to the role of AIS in neuronal excitability, physiological and pathological modifications in its organization are expected to generate neurological disorders. Multiple nonsynonymous single nucleotide polymorphisms (NS-SNPs) have been identified in the...
human P2X7 gene, which generate different mutant P2X7 receptors. Most of these mutations engender modifications in calcium permeability and are associated with diseases, including bipolar disorder, major depressive disorder, anxiety disorders, multiple sclerosis, ischemic stroke, and neuropathic pain (Jiang et al. 2013). Our results demonstrate a role of the P2X7 purinergic receptor in the damage suffered by the AIS after ischemia/reperfusion, and protection by the P2X7 antagonist, BBG, when applied in the first 3 h after ischemia induction. In this sense, it is noteworthy that 17β-oestradiol, a natural protector against ischemic injury (Perez-Alvarez et al. 2012) inhibits P2X7 receptor activity (Cario-Toumaniantz et al. 1998). Interestingly, BBG treatment after ischemia exerts a neuroprotective effect and moderately reduces both neuronal death (Arbeloa et al. 2012), and brain edema after traumatic brain injury (Kimbler et al. 2012). A previous study has shown that the AIS is disrupted before cell death when brain ischemia is induced by MCAO (Schafer et al. 2009), leading to a loss of structural and functional proteins (βIV-spectrin, ankyrin G and voltage-gated ion channels). In contrast to our study, this was not prevented by the inhibition of calcium-permeable NMDA receptors using MK-801, which in turn can increase neuronal survival after oxygen/glucose deprivation (Schafer et al. 2009). While it has been shown that P2X7 receptor levels measured by immunoblot do not change after traumatic brain injury (Kimbler et al. 2012), this receptor exhibits an increased response to ATP after ischemic insult (Wirker et al. 2005), even in the absence of an increment in P2X7 expression. However, other studies demonstrate up-regulation of P2X7 mRNA in neurons after focal cerebral ischemia (Cavaliere et al. 2004; Franke et al. 2004). In agreement with these studies our experiments indicated that the increased P2X7 receptor density induced by exogenous expression in brain slices is sufficient to disrupt AIS integrity. Moreover, the extracellular concentration of the P2X7 receptor agonist ATP is highly augmented after MCAO (Melani et al. 2005) or spinal cord injury (Wang et al. 2004). Reciprocally, ATP injection increases brain damage after ischemia (Zhang et al. 2013), while ATP depletion by ectonucleotidases may play a role in protection against brain damage after ischemia (Melani et al. 2012). Hence, an increase in either extracellular ATP or P2X7 receptor expression mediates the harmful processes activated during brain ischemia. In view of these results, P2X7 receptors seem to be a major source of calcium influx involved in AIS disruption after brain ischemia, and also a good candidate to modulate AIS function in certain physiological conditions.

In conclusion, our results support a role for the P2X7 purinergic receptor in the modulation of protein density at the AIS and neuronal excitability. As different levels of ATP and other
related purines are released into the extracellular medium in different physiological as well as pathological conditions, it is tempting to propose that other purinergic receptors, such as P2Y receptors, and purines can also contribute to AIS modulation. In fact, a selective agonist of the P2Y1 receptor, 2-MeSADP, has been identified as a neuroprotective agent in a photothrombosis model of brain ischemia (Zheng et al. 2010). Finally, further experiments are necessary to understand how the activity of P2X7 receptors and calpain are finely regulated during structural modulation of the AIS, as well as the possible participation of non-neuronal cells in the regulation of AIS function by the purinergic system.

Supplementary Material

Supplementary material can be found at: http://www.cercor.oxfordjournals.org/.

Funding

This work was supported by grants SAF2009-12249-C02-02 and SAF2009-12249-C02-01 and SAF-SAF2012-39148-C03-03 from Plan Nacional I+D+i (Spain), INSERM and Agence National de la Recherche (EXCION, EPISOM). Ana del Puerto is supported by an FPI grant from Universidad Autónoma de Madrid.

Notes

The authors acknowledge Dr Michael Seagar for critical reading of the manuscript, Dr Matthew Rasband for supplying the βIV-spectrin antibody used in this study and Mónica Tapia and Diana Sanchez-Ponce from J.J.G. laboratory for their help and comments. We want to thank also the IMeRA (L’Institut Méditerranéen de Recherches Avancées), Aix-Marseille Université and INSERM (France) for the support given to J.J.G. Conflict of Interest: None declared.
References


Friedle SA, Curet MA, Watters JJ. 2010. Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation. Recent Pat CNS Drug Discov. 5:35–45.


Cerebral Cortex August 2015, V 25 N 8 2293


